Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was USD 1 million compared to USD 1.5 million a year ago. Net loss was USD 46.07 million compared to USD 45.21 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 1.07 a year ago.